Agents that target telomerase and telomeres

Current Opinion in Biotechnology

Volumn 7, Issue 6, 1996, Pages 583-591

  Raymond, Eric ^a,b   Sun, Daekyu ^a   Chen, Shih Fong ^a   Windle, Bradford ^a   Von Hoff, Daniel D ^a  

^a Human Telomerase Research Group   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; RNA DIRECTED DNA POLYMERASE;

DNA DEGRADATION; DNA RECOMBINATION; DRUG DESIGN; DRUG TARGETING; PRIORITY JOURNAL; REVIEW; TELOMERE; TUMOR CELL;

EID: 0030560651     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(96)80068-1     Document Type: Article

References (91)

1. n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA. 85:1988;6622-6626.
2. Meyne J, Ratliff RL, Moyzis RK. Conservation of the human telomere sequence (TTAGGG)n among vertebrates. Proc Natl Acad Sci USA. 86:1989;7049-7053.
3. Hanish JP, Yanowitz JL, De Lange T. Stringent sequence requirements for the formation of human telomeres. Proc Natl Acad Sci USA. 91:1994;8861-8865.
4. Blackburn EH. Structure and function of telomeres. Nature. 350:1991;569-573.
5. Murnane JP, Yu LC. Acquisition of telomere repeat sequences by transfected DNA integrated at the site of a chromosome break. Mol Cell Biol. 13:1993;977-983.
6. Kruk PA, Rampino NJ, Bohr VA. DNA damage and repair in telomeres: relation to aging. of outstanding interest Proc Natl Acad Sci USA. 92:1995;258-262 The authors have established a method for the detection of DNA damage and repair in human telomeres. They observed that ultraviolet light induced pyrimidine dimers in telomeric DNA are repaired more efficiently than inactive, noncoding regions. Conservation of telomeric integrity appears to be necessary for the maintenance of chromosomal stability. The results of this study also indicate that the telomere repair process declines with aging.
7. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and aging. Nature. 346:1990;866-868.
8. Wright WE, Shay JW. Telomere positional effects and the regulation of cellular senescence. Trends Genet. 8:1992;193-197.
9. Harley CB, Vaziri H, Counter CM, Allsopp RC. The telomere hypothesis of cellular aging. Exp Gerontol. 27:1992;375-382.
10. Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB. Telomere end-replication problem and cell aging. J Mol Biol. 225:1992;951-960.
11. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, Greider CW, Harley CB. Telomere length predicts-replicative capacity of human fibroblasts. Proc Natl Acad Sci USA. 89:1992;10114-10118.
12. Shay JW, Wright WE, Werbin H. Loss of telomeric DNA during aging may predispose cells to cancer. Int J Cancer. 3:1993;559-563.
13. Varizi H, Shächter F, Uchida I, Wei L, Zhu X, Effros R, Cohen D, Harley CB. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet. 52:1993;661-667.
14. Allsopp RC, Chang E, Kashefi-Aazam M, Rogaev EI, Piatyszek MA, Shay JW, Harley CB. Telomere shortening is associated with cell division in vitro and in vivo. of special interest Exp Cell Res. 220:1995;194-200 This paper shows that in somatic cells that lack telomerase, telomere shortening is dependent upon cell division. The authors suggest the use of telomere length as a biomarker for replicative capacity.
15. Allsopp RC, Harley CB. Evidence for a critical telomere length in senescent human fibroblasts. of special interest Exp Cell Res. 219:1995;130-136 This paper supports the existence of a critical telomere length in senescing cells and a causal role of telomere shortening in cell senescence.
16. Windle B, McGuire S. Telomeres: the long and the short of it. Proc Am Assoc Cancer Res. 33:1992;594-595.
17. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11:1992;1921-1929.
18. Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, Bacchetti S, Hirte HW, Counter CM, Greider CW, et al. Telomerase, cell immortality, and cancer. Cold Spring Harb Symp Quant Biol. 59:1994;307-315.
19. Counter CM, Botelho FM, Wang P, Harley CB, Bacchetti S. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein - Barr virus-transformed human B lymphocytes. J Virol. 68:1994;3410-3414.
20. Counter CM, Leber B, Harley CB, Bacchetti S. Telomere length and telomerase activity in hematological malignancies [abstract]. Proc Am Assoc Cancer Res. 36:1995;555.
21. Shay JW, Piatyszek MA, Word RA, Gazdar AF, Wright WE, Kim NW, Weinrich SL, Prowse KR, Harley CB, Hiyama E, et al. You have not heard the end of it: telomeres, time, telomerase and tumors [abstract]. Proc Am Assoc Cancer Res. 36:1995;673-674.
22. Romero DP, Blackburn EH. A conserved secondary structure for telomerase RNA. Cell. 67:1991;343-353.
23. n. The authors showed that germ line tissues and tumor cell lines expressed more telomerase than normal somatic cells and tissues, which have no detectable telomerase activity. Moreover, they observed that HeLa cells transfected with an antisense lost telomeric. DNA and began to die after 23 to 26 doublings, demonstrating that human telomerase is a critical enzyme for the long-term proliferation of immortal tumor cells.
24. Lingner J, Promisel Cooper J, Cech TR. Telomerase and DNA end replication: no longer a lagging strand problem? Science. 269:1995;1533-1534.
25. Collins K. Structure end function of telomerase. Curr Opin Cell Biol. 8:1996;374-380.
26. Greider CW, Autexier C, Buchkovich K, Collins K, Blasco M, Avilion A, Mantell L, Prowse K, Harley C, Funk W, et al. Telomerase biochemistry and regulation in cellular immortalization [abstract]. Rroc Am Assoc Cancer Res. 36:1995;672.
27. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:1994;2011-2015.
28. Bacchetti S, Counter CM. Telomeres and telomerase in human cancer. Int J Cancer. 7:1995;423-432.
29. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: a prevalent market of malignant human prostate tissue. Cancer Res. 56:1996;218-222.
30. Healy KC. Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy. Oncol Res. 7:1995;121-130.
31. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human nueroblastoma outcomes. Nat Med. 1:1995;249-255.
32. Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K, Piatyszek MA, Shay JW. Telomerase activity in human breast tumors. of special interest J Natl Cancer Inst. 88:1996;116-122 Using a PCR-based telomerase activity assay, the authors examined telomerase activity in 140 breast cancer specimens, four biopsies of phyllodes tumors, 38 biopsies of noncancerous lesions (20 fibroadenomas, 17 fibrocystic diseases, 1 gynecomastia), 55 biopsies of adjacent noncancerous mammary tissues, and 33 fine needle aspirated brast samples. They detected telomerase activity in 130 of 140 (93%) breast cancers. The activity was detected in more than 95% of advanced stage tumors but in only two (4%) of 55 adjacent noncancerous tissues. The stage of the disease was correlated with telomerase activity.
33. Morin GB. Is telomerase a universal cancer target? J Natl Cancer Inst. 87:1995;859-861.
34. Harley CB, Andrews W, Chiu CP, Feng J, Funk W, Gaeta F, Hirsch K, Kim NW, Kozlowski M, Wang SS, et al. Human telomerase inhibition and cancer [abstract]. Proc Am Assoc Cancer Res. 36:1995;671-672.
35. Parkinson EK. Do telomerase antagonists represent a novel anti-cancer strategy? Br J Cancer. 73:1996;1-4.
36. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 85:1995;2315-2320.
37. Broccoli D, Young JW, De Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA. 92:1995;9082-9086.
38. Chiu CP, Dragowski V, Kim NW, Thomas TE, Harley CB, Lansdorp PM. Telomerase activity in hematopoietic progenitor cell extracts from adult bone marrow [abstract]. Proc Am Assoc Cancer Res. 36:1995;555.
39. Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, Shay JW, Ishioka S, Yamakido M. Activation of telomerase in human lymphocytes and hermatopoietic progenitor cells. J Immunol. 155:1995;3711-3715.
40. Kipling D. Telomerase: immortality enzyme or oncogene? Nat. Genet. 9:1995;104-106.
41. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortant human cells without detectable telomerase activity. of outstanding interest EMBO J. 14:1995;4240-4248 In this paper, the authors examined whether telomerase activation is always necessary for immortalization. As expected, the normal human fibroblasts tested were negative for telomerase activity and 13 DNA tumor virus-transformed cell cultures were negative in the pre-crisis stage. Of 35 immortalized telomerase activity but very long and heterogeneous telomeres. Hybrids between telomerase-negative and telomerase-positive cells showed that activation of telomerase is not sufficient for immortalization. This article suggests that the presence of lengthened or stabilized telomeres is necessary for immortalization, and that this may be achieved either by the reactivation of telomerase or by another unindentified mechanism.
42. Burger LM, Double JA, Newell DR. Correlation between cisplatin mediated inhibition of telomerase activity and cell growth in human testicular cancer cell lines [abstract]. Lobbezzo MW. Proceedings of the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. 1996;28 Kluwer Academic Publishers, Dordrecht.
43. Shay JW, Brasiskyte D, Ouellette M, Piatyszek MA, Werbin H, Ying Y, Wright WE. Analysis of telomerase and telomeres. Adolph KW. Methods in Molecular Genetics. 1994;263-280 Academic Press, New York.
44. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:1994;2011-2015.
45. De Lange T. Activation of telomerase in a human tumor. Proc Natl Acad Sci USA. 91:1994;2882-2885.
46. Greider CW, Blackburn EH. Telomeres, telomerase and cancer. Sci Am. 274:1996;92-97.
47. De Lange T. Activation of telomerase in a human tumor. Proc Natl Acad Sci USA. 91:1994;2882-2885.
48. Harley CB, Villeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev. 5:1995;249-255.
49. Axelrod N. Of telomeres and tumors. Nat Med. 2:1996;158-159.
50. Cohn M, Blackburn EH. Telomerase in yeast. Science. 269:1995;396-400.
51. Lue NF, Wang JC. ATP-dependent processivity of a telomerase activity from Saccharomyces cerevisiae. J Biol Chem. 270:1995;21453-21456.
52. Lin JJ, Zakian VA. An in vitro assay for Saccharomyces telomerase requires EST1. Cell. 81:1995;1127-1135.
53. Zhu M, Kumar R, Mandal M, Sharma N, Sharma HW, Dhingra U, Sokoloski JA, Hsiao R, Narayanan R. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci USA. 93:1996;6091-6095.
54. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines [abstract]. Proc Am Assoc Cancer Res. 37:1996;559.
55. Qiu M, Windle B. Analysis of processive and non-processive telomerase activity using a sensitive and quantitative ligation and PCR-based assay [abstract]. Proc Am Assoc Cancer Res. 37:1996;561.
56. Sun D, Chen S-F, Von Hoff D. A sensitive and rapid assay method of human telomerase using dynabeads [abstract]. Lobbezzo MW. Proceedings of the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. 71:1996;Kluwer Academic Publishers, Dordrecht.
57. Maine IP, Windle B, Chen SF. In vitro investigations of processive and non-processive telomerase activities [abstract]. Proc Am Assoc Cancer Res. 36:1995;554.
58. Maine IP, Chen SF, Windle B. Interaction between telomeric oligonucleotide primers and CHO non-processive telomerase [abstract]. Proc Am Assoc Cancer Res. 37:1996;561.
59. Park VM, Gustashaw KM, Wathen TM. The presence of interstitial telomeric sequences in constitutional chromosome abnormalities. Am J Hum Genet. 50:1992;914-923.
60. Reimann N, Rogalla P, Kazmierczak B, Bonk U, Nolte I, Grzonka T, Bartnitzke S, Bullerdiek J. Evidence that metacentric and submetacentric chromosomes in canine tumors can result from telomeric fusions. Cytogenet Cell Genet. 67:1994;81-85.
61. Chadeneau C, Siegel P, Harley CB, Muller WJ, Bacchetti S. Telomerase activity in normal and malignant murine tissues. of outstanding interest Oncogene. 11:1995;893-898 This study characterizes an animal model for inhibition studies, and invetigates telomerase activity during mammary tumorigenesis in transgenic mice overexpressing the neu gene. The authors detected activity in primary mammary tumors and lung metastases but also in normal mammary glands and other organs. Activity was elevated in tumors versus normal tissues and was enhanced by short-term culturing of normal cells. They propose this mouse model of tumorigenesis for experimental systems assessing the outcome of in vivo inhibition of telomerase in malignant and normal cells.
62. Prowse KR, Avilion AA, Greider CW. Identification of a nonprocessive telomerase activity from mouse cells. Proc Natl Acad Sci USA. 90:1993;1493-1497.
63. Bednarek A, Budunova I, Slaga TJ, Aldaz CM. Increased telomerase activity in mouse skin premalignant progression. Cancer Res. 55:1995;4566-4569.
64. Bacchetti S, Counter CM, Chadeneau C, Gupta J, Harley CB, Leber B, Gallinger S, Hirte HW, Siegel P, Muller WJ. Telomerase activity in human and murine somatic tissues and tumors [abstract]. Proc Am Assoc Cancer Res. 36:1995;674.
65. Burger AM, Bibby MC, Double JA. Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a potential target for cancer chemotherapy [abstract]. Proc Am Assoc Cancer Res. 37:1996;495.
66. Olivero OA, Gomez DE, Kassim A, Windle BE. Preferential Incorporation of 3′-azido-2′,3′ dideoxythymidine (AZT) into telomeric DNA of Chinese hamster ovary (CHO) cells [abstract]. Proc Am Assoc Cancer Res. 35:1994;340.
67. Olivero OA, Poirier MC. Z-DNA configuration in chinese hamster ovary cells as a preferential target for 3′azido-2′-3′-dideoxythymidine (AZT) incorporation [abstract]. Proc Am Assoc Cancer Res. 33:1992;171.
68. Olivero OA, Gomez DE, Kassim A, Windle BE. Telomeric DNA of CHO cells target for AZT (3′-azido-2′,3′-dideoxythymidine) incorporation through telomerase [abstract]. Proc Am Assoc Cancer Res. 36:1995;556.
69. Chen SF, Maine IP, Windle B. Effect of 3′-azidothymidine triphosphate (AZTTP) and 3′-azidothymidine (AZT) on telomerase activity and telomere function [abstract]. Proc Am Assoc Cancer Res. 36:1995;554.
70. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. of outstanding interest Mol Cell Biol. 16:1996;53-65 This study analyzes telomere maintenance in two immortalized human cell lines and determines whether known inhibitors of retroviral reverse transcriptases perturb telomere lengths and growth rates of cells in culture.
71. Joshi SS, Palen BN, Mata JE, Iversen PL. Growth inhibitory effects of telomere mimic-oligonucleotides on human leukemia/lymphoma cells in vitro [abstract]. Proc Am Assoc Cancer Res. 36:1995;441.
72. Iversen PL, Pirruccello SJ, Mata JE, Joshi SS. Antisense oligonucleotides which demonstrates tumor specific action also inhibit telomerase in vitro [abstract]. Proc Am Assoc Cancer Res. 36:1995;412.
73. Ohmura H, Tahara H, Suzuki M, Ide T, Shimizu M, Yoshida MA, Tahara E, Shay JW, Barrett JC, Oshimura M. Restoration of the cellular senescence program and repression of telomerase by human chromosome 3. Jpn J Cancer Res. 86:1995;899-904.
74. Ahmed SC. Telomeric acids: C-strand structure and a telomerase RNA mutant [abstract]. Diss Abstr Int [B]. 56:1995;623.
75. Edington KG, Loughran OP, Berry IJ, Parkinson EK. Cellular immortality: a late event in the progression of human squamous cell carcinoma of the head and neck associated with p53 alteration and a high frequency of allele loss. Mol Carcinog. 13:1995;254-265.
76. Chadeneau C, Hay K, Hirte HW, Gallinger S, Bacchetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res. 55:1995;2533-2536.
77. Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, Murakami Y, Kodama T, Piatyszek MA, Shay JW, Matsuura Y. Telomerase activity in gastric cancer. Cancer Res. 55:1995;3258-3262.
78. Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, Piatysek MA, Shay JW. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst. 87:1995;895-902.
79. Lin Y, Miyamamoto H, Fujinami K, Uemura H, Hosaka M, Iwasaki Y, Kubota Y. Telomerase activity in human bladder cancer. Clin C Res. 2:1996;929-932.
80. Ezzell C. The telomerase-cancer connection: will exceptions make a new rule? J NIH Res. 7:1995;41-45.
81. Wang S, Zakian VA. Telomere-telomere recombination provides an express pathway for telomere acquisition. Nature. 345:1990;456-458.
82. Lundblad V, Blackburn EH. An alternative pathway for yeast telomere maintenance rescues est- senescence. Cell. 73:1993;347-360.
83. Levis RW, Ganesan R, Houtchens K, Tolar LA, Sheen FM. Transposons in place of telomeric repeats at a Drosophila telomere. Cell. 75:1993;1083-1093.
84. Biessmann H, Masson JM, Ferry K, D'Hulst M, Valgeirdottir K, Traverse KL, Pardue ML. Addition of telomere-associated HRT DNA sequences "heals" broken chromosome ends in Drosophila. Cell. 61:1990;663-673.
85. Windle B, Maine IP, Wajima M, Chen SF. Nucleotide specificity and inhibition of telomerase, and cellular resistance to telomerase inhibition [abstract]. Proc Am Assoc Cancer Res. 36:1995;556.
86. Thompson B, Salazar M, Sun D, Jenkins T, Neidle S, Hurley L. Telomerase inhibition by G-quartet interactive compounds [abstract]. Lobbezzo MW. Proceedings of the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. 71:1996;Kluwer Academic Publishers, Amsterdam.
87. Salazar M, Thompson B, Kerwin SM, Hurley L. Unwinding of telomeric hybrids is facilated by G-quarter formation [abstract]. Lobbezzo W. Proceedings of the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. 1996;71 Kluwer Academic Publishers, Dordrecht.
88. Fletcher TM, Chen S-F. The effect of 7-deaza-2′- deoxyguanosine-5′-triphosphate and 7-deaza-2′- deoxyadenosine-5′-triphosphate on telomerase activity [abstract]. Lobbezzo MW. Proceedings of the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. 1996;71 Kluwer Academic Publishers, Dordrecht.
89. De Lange T. Human telomeres are attached to the nuclear matrix. EMBO J. 11:1992;717-724.
90. Chong L, Van Steensel B, Broccoli D, Erdjument-Bromage H, Hanist J, Tempst P, De Lange T. A human telomeric protein. Science. 270:1995;1663-1667.
91. Zahler AM, Williamson JR, Cech TR, Prescott DM. Inhibition of telomerase by G-quarter DNA structures. Nature. 350:1991;708-720.